NervGen Pharma Corp. (NGEN) - Total Liabilities
Based on the latest financial reports, NervGen Pharma Corp. (NGEN) has total liabilities worth $15.21 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NervGen Pharma Corp. equity growth rate to track the company's year-over-year net asset growth rate.
NervGen Pharma Corp. - Total Liabilities Trend (2018–2025)
This chart illustrates how NervGen Pharma Corp.'s total liabilities have evolved over time, based on quarterly financial data.
NervGen Pharma Corp. Competitors by Total Liabilities
The table below lists competitors of NervGen Pharma Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Astral Resources NL
AU:AAR
|
Australia | AU$4.92 Million |
|
Mayer Steel Pipe Corp
TW:2020
|
Taiwan | NT$5.07 Billion |
|
Ha Tien 1 Cement JSC
VN:HT1
|
Vietnam | ₫2.51 Trillion |
|
Gipta Ofis Kirtasiye ve Promosyon Ãrünleri Imalat Sanayi A.S.
IS:GIPTA
|
Turkey | TL692.51 Million |
|
Sierra Metals Inc.
TO:SMT
|
Canada | CA$269.76 Million |
|
PULSION Medical Systems SE
MU:PUS
|
Germany | €14.54 Million |
|
Honma Golf Limited
F:HF5
|
Germany | €13.30 Billion |
|
Sinphar Pharmaceutical Co Ltd
TW:1734
|
Taiwan | NT$2.61 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down NervGen Pharma Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NervGen Pharma Corp. (NGEN) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NervGen Pharma Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NervGen Pharma Corp. (2018–2025)
The table below shows the annual total liabilities of NervGen Pharma Corp. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.73 Million | +16.77% |
| 2024-12-31 | $16.90 Million | +10.83% |
| 2023-12-31 | $15.25 Million | +47.70% |
| 2022-12-31 | $10.32 Million | +850.27% |
| 2021-12-31 | $1.09 Million | +43.54% |
| 2020-12-31 | $756.78K | -20.27% |
| 2019-12-31 | $949.14K | +63.29% |
| 2018-12-31 | $581.26K | -- |
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more